These findings offer novel mechanistic insight into how metabolic reprogramming amplifies innate immune responses and provide a compelling rationale for targeting glycolysis-STING signaling as a therapeutic strategy for LF and liver cirrhosis. This evidence concerns the gene STING1 and cirrhosis of liver.